Navigation Links
Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
Date:12/18/2018

Nativis, Inc., a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM.

The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site.

“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”

The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.

“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”

Rivera concluded, “We are looking forward to obtaining data from this ongoing clinical study for treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families.”

About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.

Media Contact:
Dennis Kroft
dkroft(at)nativis(dot)com
201-602-8354

Read the full story at https://www.prweb.com/releases/nativis_announces_publication_of_study_in_patients_with_recurrent_glioblastoma_rgbm/prweb15991523.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Nanomedical Diagnostics Announces Office Move to Accommodate Company Growth
2. Urological Associates of Southern Arizona Announces Dr. Kenneth Choi’s Designation as UroLift® Center of Excellence
3. Fastec Imaging Announces OEM Partner Program
4. EARTHRES Adds to Executive Team - Announces New Chief Operating Officer
5. Cloudponics Announces Holiday Discount For Leading Product, GroBox
6. Immuno-Oncology 360° (IO360°) NYC Gathering Announces Keynotes for the 5th Annual Event
7. FDAnews Announces — Early Bird Pricing Ends on Nov. 8 for Emerging Trends in Medical Device Regulation and Quality, Dec. 6, 2018, Washington, DC
8. Karius Announces the Clinical Investigator Award for Applied Pediatric Infectious Disease Genomics
9. Myoscience Announces Commercial Release of Nerve Stim Enabled iovera° Smart Tip
10. Slone Partners, Where People Are Our Science®, Announces Insights: Scientific Healthcare Investing 2018 Panel Event With Leaders In The Investment Community
11. Ajinomoto Health & Nutrition's Amino Acid Division Announces Price Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2019)... ... , ... Join this live webinar on Thursday, March 21, 2019 ... bioinformaticians focus on data analysis without worrying about data management-related activities. , Clinical ... Some sources of data include:, , Clinical Trial Management Systems ...
(Date:3/1/2019)... ... February 28, 2019 , ... Teresa Krabbe, Ph.D., a ... of the Technical University Munich, has been awarded an xCELLigence Research Grant for her ... oncolytic virus platform. , Oncolytic viruses represent an exciting new aspect in ...
(Date:2/27/2019)... Md. (PRWEB) , ... February 26, 2019 , ... Circulomics ... of high molecular weight (HMW) DNA for long-read sequencing library preparation. , This ... DNA. The gentle processing ensures that HMW DNA is not damaged and recovered with ...
Breaking Biology News(10 mins):
(Date:3/15/2019)... SÃO PAULO and ATLANTA (PRWEB) , ... ... ... GranBio completed the acquisition of 100% equity in American Process Inc. and ... assets include the Alpena Biorefinery in Alpena Michigan, the Thomaston Biorefinery and ...
(Date:3/14/2019)... ... , ... The growth in the number and complexity of regulations as well ... intelligence (RI) systems are not keeping with ... faster and cheaper. With a diversity of information sources, identifying and analyzing context based ...
(Date:3/14/2019)... ... March 14, 2019 , ... ON NOVEMBER ... Canadian partner, the Eye Machine Canada Inc., had been given approval to begin ... treating Age-Related Macular Degeneration (AMD). , The previous month, the medical devices bureau ...
(Date:3/14/2019)... BETHESDA, Md. (PRWEB) , ... March 13, 2019 ... ... announced its 2019 ISPE Europe Biotechnology Conference , taking place in ... for sharing biotechnology best practices, technical and operational solutions, and innovative approaches. ...
Breaking Biology Technology: